An Open Label Single Arm Clinical Study To Evaluate The Combined Effect Of Virechana And Trayantyadi Kashaya In Alcoholic Liver Disease

Abstract

Alcoholic Liver Disease (ALD) comprise a spectrum of diseases associated with chronic Alcohol consumption ranging from Alcohol associated Fatty Liver Disease and Steatohepatitis (Alcoholic Hepatitis) to move advanced liver diseases including from fibrosis to cirrhosis. World Health Organisation (WHO) estimates that about 2 billion people worldwide consume alcohol beverages and 76.3 million have diagnosable alcohol disorder. According to National Family Health Survey (NFH-5) 2019-2021 has found 55% of Indians consume alcohol. According to latest WHO data published in May 2018, Liver disease deaths in India reached 216,865 or 2.44% of total death. Death rate is 21.96 per 100,000 of population. There is a high prevalence of Alcoholic Liver Disease in India and about 50% cases of Cirrhosis in India may be due to alcohol abuse. Quantity and duration of Alcohol intake are the most important risk factor for development of ALD. Alcoholic Fatty Liver is the earliest change and is almost universally present in heavy alcoholics. Among the Alcoholic Fatty Liver, 34.3% may end up with Cirrhosis. It is generally a benign condition with abstinence. Alcoholic Hepatitis occurs in 10% to 35% of heavy drinkers who develop necro inflammation with or without fat infiltration. Virechana is the first line of management for Pitta, Pittakapha, and Pittashayagata vikara. Trayantyadi Kashaya include Trayanti, as one of the main ingredients which is directly indicated in Yakrit Vikaras as mentioned in Priyanighantu. The study comprises of 30 subjects. These subjects were selected on the basis of inclusion and exclusion criteria with detailed clinical history, physical examination and other desired investigations. So, in the present study an effort has been put forth to evaluate combined effect of Virechana and Trayantyadi Kashaya in Alcoholic liver disease.